| Similar Articles |
|---|
 |
The Motley Fool
April 30, 2008
Brian Lawler |
Alexza Advances 2 More Drugs The pharmaceutical company's compounds keep zipping through clinical trials.   |
The Motley Fool
December 29, 2006
Brian Lawler |
No Pain for Alexza December's been good to lots of pharmas, but Alexza in particular has something to thank Santa for. Investors should pay close attention when Alexza issues its AZ-001 trial results next year. |
The Motley Fool
September 21, 2007
Brian Lawler |
Alexza Advances The pharmaceutical company's schizophrenia drug is ready for phase 3 testing, which will begin in the first quarter of 2008. Investors, take note. |
The Motley Fool
August 14, 2007
Brian Lawler |
Alexza's Announcement Alexza files second-quarter results and announces the expansion of its drug pipeline. The biotech company estimates that its technology could work with nearly 200 already marketed drugs. |
The Motley Fool
April 2, 2007
Brian Lawler |
A Good Week for Alexza The pharma reports positive clinical trial results. Investors, take note. |
The Motley Fool
April 11, 2007
Brian Lawler |
Get Rich With These Guys Regardless of what type of long-term investment strategy you use, finding companies created under the auspices of proven entrepreneurs such as Moll, Zaffaroni, and Mann and then sticking with them for the long run is one path to investing riches. |
The Motley Fool
October 11, 2010
Travis Hoium |
Alexza Shares Plunged: What You Need to Know Alexza Pharmaceuticals shares fell 52% today after the Food and Drug Administration did not clear the company's new drug, AZ-004. |
The Motley Fool
December 28, 2007
Brian Lawler |
Endo and Alexza Team Up Endo Pharmaceuticals and Alexza Pharmaceuticals announce a collaboration deal for an early-stage Alexza drug. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool
June 11, 2007
Brian Lawler |
Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
Pharmaceutical Executive
February 1, 2006
Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. |
The Motley Fool
April 2, 2008
Brian Lawler |
Alexza Establishes a Cash Pipeline Alexza Pharmaceuticals announces that it has signed a deal that will provide it with up to $50 million over the next two years. Investors take note. |
Chemistry World
April 2011 |
Column: In the Pipeline If you look over the whole pharmacopeia, you'll see there are a lot of compounds that got their start as natural products. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
Chemistry World
January 2012 |
Column: In the pipeline Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about |
The Motley Fool
April 26, 2007
Brian Lawler |
Brazil's Boneheaded Drug Move Brazil already receives a steep discount on the price that Merck charges it for its HIV compounds. Nevertheless, it wants still lower prices to help reduce the government's costs associated with supplying drugs to those living with HIV/AIDS. |
The Motley Fool
January 16, 2008
Brian Lawler |
Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
Chemistry World
August 2009
Derek Lowe |
Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder |
